Has Emcure Pharma declared dividend?

No Dividend History Available

Who are the peers of the Emcure Pharma?

Emcure Pharma's peers include Ipca Labs, Ajanta Pharma, Gland Pharma, Wockhardt, Piramal Pharma, J B Chemicals, Pfizer, ERIS Lifescience, and Astrazeneca Pharma. In terms of performance, Wockhardt has the highest 1-year return at 116.70%, while Emcure Pharma's return is -0.17%.

Peers: The peers of Emcure Pharma are Ipca Labs, Ajanta Pharma, Gland Pharma, Wockhardt, Piramal Pharma, J B Chemicals &, Pfizer, ERIS Lifescience, and Astrazeneca Phar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Ajanta Pharma, while Good management risk is found at Ipca Labs, Gland Pharma, J B Chemicals &, Emcure Pharma, Pfizer, ERIS Lifescience, and Astrazeneca Phar. Average management risk is present at Wockhardt and Piramal Pharma. For Growth, Excellent growth is seen at OneSource Speci., while Good growth is noted at Wockhardt and Piramal Pharma, and Average growth is found at Ipca Labs, J B Chemicals &, and Emcure Pharma. Below Average growth is observed at Ajanta Pharma, Gland Pharma, Pfizer, ERIS Lifescience, and Astrazeneca Phar. In terms of Capital Structure, Excellent capital structure is noted at Ipca Labs, Ajanta Pharma, Gland Pharma, and the rest, while Good capital structure is found at Emcure Pharma, and Below Average capital structure is present at Wockhardt and Piramal Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wockhardt at 116.70%, while the peer with the lowest is J B Chemicals & at -7.94%. Emcure Pharma's own 1-year return is -0.17%, which is higher than J B Chemicals & but lower than most peers. Additionally, Wockhardt and Piramal Pharma are among the peers whose six-month return is negative.

What does Emcure Pharma do?

Emcure Pharmaceuticals Ltd is a large-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of ₹21,162 Cr and a net profit of ₹1,890 Cr for March 2025. It has a market cap of ₹25,696 Cr and key metrics include a P/E ratio of 38.00 and a return on equity of 15.49%.

Overview:<BR>Emcure Pharmaceuticals Ltd is a large-cap company operating in the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>Emcure Pharmaceuticals Limited was originally incorporated in 1981 as a private company and later converted into a public company in 2001. The most recent quarterly results report net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 21,162 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1,890 Cr (Quarterly Results - Mar 2025) <BR>Market-cap: INR 25,696 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 38.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.18 <BR>Return on Equity: 15.49% <BR>Price to Book: 5.81 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the top shareholders of the Emcure Pharma?

The top shareholders of Emcure Pharma include Satish R Mehta with 39.79%, Bc Investments IV Limited at 8.68%, and individual investors with 5.51%. Mutual funds hold 2.73%, while foreign institutional investors own 3.07%, with pledged promoter holdings at 0.0406%.

The top shareholders of Emcure Pharma include the promoters, with Satish R Mehta holding the highest stake at 39.79%. Other significant shareholders are Bc Investments IV Limited, which holds 8.68%, and individual investors who collectively own 5.51%. Additionally, mutual funds have a presence with 21 schemes holding 2.73%, while foreign institutional investors (FIIs) hold 3.07% through 48 different entities. The pledged promoter holdings are relatively low at 0.0406%.

How big is Emcure Pharma?

As of 24th July, Emcure Pharmaceuticals Ltd has a market capitalization of 27,118.00 Cr, with recent net sales of 7,896.00 Cr and a net profit of 681.33 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Emcure Pharmaceuticals Ltd has a market capitalization of 27,118.00 Cr, classified as Large Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 7,896.00 Cr, while the sum of Net Profit for the same period is 681.33 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 2,952.28 Cr and Total Assets valued at 7,709.37 Cr.

Is Emcure Pharma overvalued or undervalued?

As of September 23, 2025, Emcure Pharma is considered overvalued with a PE Ratio of 33.30, an EV to EBITDA of 16.59, and a Price to Book Value of 5.65, underperforming the Sensex with a year-to-date return of -8.07%.

As of 23 September 2025, Emcure Pharma's valuation grade has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE Ratio of 33.30, an EV to EBITDA of 16.59, and a Price to Book Value of 5.65. <BR><BR>In comparison to its peers, Emcure Pharma's PE Ratio is slightly lower than Sun Pharma's 34.11 but significantly higher than Cipla's 22.93, indicating a premium valuation relative to some competitors. Additionally, Emcure's PEG Ratio stands at 0.00, which is notably lower than the industry average, suggesting potential growth concerns. Recent stock performance has underperformed against the Sensex, with a year-to-date return of -8.07% compared to the Sensex's gain of 5.07%, reinforcing the notion that the stock may be overvalued.

When is the next results date for Emcure Pharma?

Emcure Pharma will announce its results on 11 November 2025.

Emcure Pharma is scheduled to declare its results on 11 November 2025.

Is Emcure Pharma technically bullish or bearish?

As of November 4, 2025, Emcure Pharma shows a mildly bullish trend overall, despite some bearish signals from weekly indicators like MACD and Bollinger Bands.

As of 4 November 2025, the technical trend for Emcure Pharma has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and Bollinger Bands are showing mildly bearish signals. The RSI has no signal on both the weekly and monthly time frames, suggesting a lack of momentum. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish indicators on the weekly charts.

Are Emcure Pharma latest results good or bad?

Emcure Pharmaceuticals' Q2 FY26 results are positive, with a net profit increase of 17.64% quarter-on-quarter and 25.13% year-on-year, alongside improved operating margins. However, the stock's high valuation may limit market enthusiasm despite strong operational performance.

Emcure Pharmaceuticals' latest results for Q2 FY26 can be considered quite positive. The company reported a net profit of ₹243.46 crores, which reflects a significant increase of 17.64% quarter-on-quarter and 25.13% year-on-year. Additionally, net sales grew by 8.06% sequentially, reaching ₹2,269.82 crores, and year-on-year revenue growth stood at 13.38%.<BR><BR>The operating margin improved to 20.95%, marking the highest level in eight quarters, indicating effective cost management and operational efficiency. Furthermore, the return on equity (ROE) of 15.50% showcases strong capital efficiency.<BR><BR>Despite these strong operational metrics, the stock has faced some market skepticism, primarily due to its high valuation, trading at 35.86 times trailing earnings. This premium valuation leaves limited room for error, which may explain the muted market reaction to the positive results.<BR><BR>Overall, while the operational performance is strong and shows a positive trend, the high valuation presents a cautionary note for investors.

How has been the historical performance of Emcure Pharma?

Emcure Pharma has demonstrated strong historical performance, with net sales increasing from 5,985.81 Cr in March 2023 to 7,896.00 Cr in March 2025, alongside rising profits and improved earnings per share. Despite a decline in cash flow from operating activities, the overall financial metrics indicate robust growth in sales and profitability.

Answer:<BR>Emcure Pharma has shown a positive trend in its historical performance, with significant growth in net sales and profits over the past three years.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Emcure Pharma reported net sales of 7,896.00 Cr, an increase from 6,658.25 Cr in March 2024 and 5,985.81 Cr in March 2023. The total operating income mirrored this growth, reaching 7,896.00 Cr in March 2025. The company's total expenditure also rose to 6,421.62 Cr, up from 5,428.53 Cr in the previous year. Operating profit (PBDIT) increased to 1,541.64 Cr in March 2025, compared to 1,286.71 Cr in March 2024. Profit before tax reached 971.35 Cr, up from 727.23 Cr, and profit after tax was 707.47 Cr, an increase from 527.58 Cr in the prior year. The consolidated net profit for March 2025 was reported at 681.33 Cr, up from 498.18 Cr in March 2024. The company's earnings per share also improved, reaching 35.96 in March 2025 from 27.5 in March 2024. On the balance sheet, total assets increased to 8,121.73 Cr in March 2025, while total liabilities rose to 8,121.73 Cr as well. The cash flow from operating activities was 851.00 Cr, down from 1,097.00 Cr in the previous year, resulting in a net cash outflow of 58.00 Cr for March 2025. Overall, Emcure Pharma's financial metrics indicate a robust growth trajectory in sales and profitability, despite some fluctuations in cash flow.

Should I buy, sell or hold Emcure Pharma?

Which are the latest news on Emcure Pharma?

Why is Emcure Pharma falling/rising?

As of 15-Dec, Emcure Pharmaceuticals Ltd's stock price is declining, currently at Rs 1,396.00, down 3.03%. Despite some positive management efficiency indicators, the stock's long-term growth prospects are poor, with a year-to-date decline of 2.92% compared to the Sensex's gain of 9.05%.

As of 15-Dec, Emcure Pharmaceuticals Ltd's stock price is falling, currently at Rs 1,396.00, which represents a decline of Rs 43.6 or 3.03%. This decrease is reflected in today's performance, where the stock has underperformed its sector by 2.76%. The stock reached an intraday low of Rs 1,386.5, marking a drop of 3.69%. <BR><BR>Despite some positive indicators, such as a high management efficiency with a return on capital employed (ROCE) of 21.37% and a strong ability to service debt, the stock's long-term growth prospects appear poor. The operating profit has only grown at an annual rate of 8.80% over the last five years, which raises concerns about its valuation, as indicated by a high enterprise value to capital employed ratio of 4.7. <BR><BR>Additionally, while there has been an increase in institutional investor participation, with a 1.96% rise in their stake, the stock's year-to-date performance shows a decline of 2.92%, contrasting sharply with the Sensex's gain of 9.05% over the same period. This overall context of underperformance and concerns about growth potential contribute to the current decline in Emcure Pharmaceuticals' stock price.